Onkológia 4/2009
Current indications for pemetrexed in the treatment of non-small cell lung cancer
The approved indications for pemetrexed for advanced/metastatic non-small cell lung cancer (NSCC) with mostly nonsquamous histology - in the first line therapy in combination with cisplatin and as monotherapy in the second line treatment - are mainly based on the results of randomized studies JMDB and JMEI. Furthermore, the other two randomized trials - NS01 a JMEN - have suggest the better efficacy of pemetrexed for nonsquamous NSCC. In the review are resumed the outcomes of these studies that justify/support the current position of pemetrexed in the treatment of NSCC.
Keywords: pemetrexed, nonsquamous non-small cell lung cancer
